EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome-driven dosimetry optimization for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization

Jiaxi Hu iD, Robert Seifert, Carlos Vinicius Gomes, Yizhou Chen, Yibin Liu, Warissara Jutidamrongphan, Michelle Amon, Jiahui Wang, Song Xue, Axel Rominger, Ali Afshar-Ormieh, Kuangyu Shi

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07936-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Jiaxi Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Radiometry, Radiopharmaceuticals, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Internal dosimetry in radiopharmaceutical therapy (RPT) traditionally prioritizes methodological optimization driven by physical dose accuracy. However, even recommended multiple-time-point (MTP) dosimetry remains subject to uncertainties related to limited sampling schedules, pharmacokinetic, and curve-fitting modeling assumptions. In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [ 177 Lu]Lu-PSMA-617 RPT, we explored an outcome-driven dosimetry optimization strategy by comparing MTP and single-time-point (STP) dosimetry, and identifying optimal time-points (TPs) for Hänscheid approximation based on therapy outcomes.

Methods

Clinical and image data from 50 patients were retrospectively analyzed. Transient treatment-emergent adverse events (TEAEs) and prostate-specific antigen (PSA) response were monitored following CTCAE v5.0 and PCWG3. Cycle-level mean absorbed doses ( MTPD tox , and 1d- , 2d- , 3d-STPD tox based on single SPECT acquisitions at 1-, 2-, 3-day(s) p.i.) were computed for organs-at-risk and whole-body tumors. Additionally, cumulative absorbed doses ( STPD cum & MTPD cum ) were derived for whole-body tumors.

Results

Bone marrow STP dosimetry correlated significantly with anaemia grading ( 1d-STPD tox : Spearman’s ρ=0.35; 2d-STPD tox : Spearman’s ρ=0.41; 3d-STPD tox : Spearman’s ρ=0.46; all p adj

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiometryRadiopharmaceuticalsDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantHumansMaleTime FactorsRadioisotopesTreatment OutcomeRetrospective StudiesAgedMiddle AgedProstate-Specific AntigenRadiotherapy Dosage

Stichwörter der Autor:innen

DosimetryProstate cancerRadiopharmaceutical therapyTheranostics[ 177 Lu]Lu-PSMA-617

Substanzen

RadiopharmaceuticalsDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177RadioisotopesPSMA-617Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
  • Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Taipa, Macau SAR, China.
  • Graduate School for Health Sciences, University of Bern, Bern, Switzerland.
  • Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland. kuangyu.shi@unibe.ch.

ORCID-Profile: Jiaxi Hu

Förderung

  • University of Bern

Zitieren

APA

Hu, J., Seifert, R., Gomes, C. V., Chen, Y., Liu, Y., Jutidamrongphan, W., Amon, M., Wang, J., Xue, S., Rominger, A., Afshar-Ormieh, A., & Shi, K. (2026). Outcome-driven dosimetry optimization for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07936-w

Vancouver

Hu J, Seifert R, Gomes CV, Chen Y, Liu Y, Jutidamrongphan W, et al. Outcome-driven dosimetry optimization for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07936-w

BibTeX
@article{Hu2026,
  author = {Hu, Jiaxi and Seifert, Robert and Gomes, Carlos Vinicius and Chen, Yizhou and Liu, Yibin and Jutidamrongphan, Warissara and Amon, Michelle and Wang, Jiahui and Xue, Song and Rominger, Axel and Afshar-Ormieh, Ali and Shi, Kuangyu},
  title = {Outcome-driven dosimetry optimization for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07936-w}
}
Kostenlos starten →